1887

Abstract

The postantibiotic effect (PAE) of tomopenem was determined aftera 2 h exposure of two strains of meticillin-susceptible and meticillin-resistant (MSSA and MRSA), and imipenem-susceptibleand imipenem-resistant , to tenfold the respectiveMIC. The PAEs on MSSA and were approximately 1 hand they were comparable to those of meropenem. The PAE on MRSA was 1.5 to3 h, equal to or longer than those of vancomycin. The PAEs of tomopenemnot only were found for MRSA, but also were present in the imipenem-resistant tested.

Loading

Article metrics loading...

/content/journal/jmm/10.1099/jmm.0.017905-0
2010-04-01
2021-04-20
Loading full text...

Full text loading...

/deliver/fulltext/jmm/59/4/438.html?itemId=/content/journal/jmm/10.1099/jmm.0.017905-0&mimeType=html&fmt=ahah

References

  1. Bax R. P., Bastain W., Featherstone A., Wilkinson D. M., Hutchison M., Haworth S. J. 1989; The pharmacokineticsof meropenem in volunteers. J Antimicrob Chemother 24 (Suppl. A):311–320
    [Google Scholar]
  2. CLSI 2006 Methods for DilutionAntimicrobial Susceptibility Tests for Bacteria that Grow Aerobically ,7th edn, approved standard M7–A7 Wayne, PA: Clinical and LaboratoryStandards Institute;
    [Google Scholar]
  3. Craig W. A., Gudmundsson S. 1996; The postantibiotic effect. In Antibiotics in Laboratory Medicine , 4th edn. pp 296–329 Edited by Lorian V. Baltimore, MD: Williams &Wilkins;
    [Google Scholar]
  4. Drusano G. L., Standiford H. C. 1985; Pharmacokinetic profile of imipenem/cilastatin in normal volunteers. Am J Med 78 (Suppl. 6A):47–53
    [Google Scholar]
  5. Gould I. M., Jason A. C., Milne K. 1989; Use of the Malthus microbial growth analyser to study the postantibiotic effect of antibiotics. J Antimicrob Chemother 24:523–531 [CrossRef]
    [Google Scholar]
  6. Hanssen A. M., Ericson Solid J. U. 2006; SCC mec in staphylococci: genes on the move. FEMS Immunol Med Microbiol 46:8–20 [CrossRef]
    [Google Scholar]
  7. Koga T., Abe T., Inoue H., Takenouchi T., Kitayama A., Yoshida T., Masuda N., Sugihara C., Kakuta M. other authors 2005; In vitro and in vivo antibacterial activity of CS-023 (RO4908463),a novel parenteral carbapenem. Antimicrob Agents Chemother 49:3239–3250 [CrossRef]
    [Google Scholar]
  8. Koga T, Masuda N, Kakuta M, Namba E, Sugihara C, Fukuoka T. 2008; Potent in vitro activityof tomopenem (CS-023) against methicillin-resistant Staphylococcusaureus and Pseudomonas aeruginosa . Antimicrob AgentsChemother 52:2849–2854
    [Google Scholar]
  9. Koga T, Sugihara C, Kakuta M, Masuda N, Namba E, Fukuoka T. 2009; Affinity of tomopenem (CS-023)for penicillin-binding proteins in Staphylococcus aureus , Escherichiacoli, and Pseudomonas aeruginosa . Antimicrob AgentsChemother 53:1238–1241
    [Google Scholar]
  10. MacGowan A. P., Bowker K. E., Noel A. R. 2008; Pharmacodynamics of the antibacterial effect and emergenceof resistance to tomopenem, formerly RO4908463/CS-023, in an in vitropharmacokinetic model of Staphylococcus aureus infection. Antimicrob Agents Chemother 52:1401–1406 [CrossRef]
    [Google Scholar]
  11. Odenholt I., Isaksson B., Nilsson L., Cars O. 1989; Postantibiotic and bactericidal effect of imipenemagainst Pseudomonas aeruginosa . Eur J Clin Microbiol InfectDis 8:136–141
    [Google Scholar]
  12. Odenholt-Tornqvist I., Löwdin E., Cars O. 1991; Pharmacodynamic effects of subinhibitory concentrationsof β -lactam antibiotics in vitro. Antimicrob AgentsChemother 35:1834–1839
    [Google Scholar]
  13. Ohya S., Abe T., Ishii C., Kakuta M., Masuda N., Utsui Y., Kuwahara S. 2000; R-115685, a novel parenteralcarbapenem: in vitro antibacterial activity. In Program and Abstractsof the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy , abstract F-1230 Toronto, Canada: American Society for Microbiology;
    [Google Scholar]
  14. Quale J., Bratu S., Gupta J., Landman D. 2006; Interplay of efflux system, ampC, and oprD expression incarbapenem resistance of Pseudomonas aeruginosa clinical isolates. Antimicrob Agents Chemother 50:1633–1641 [CrossRef]
    [Google Scholar]
  15. Sesoko S., Morita K., Tajima N., Nakashima M. 2006; Safety, tolerability, and pharmacokinetics (PK)of CS-023, a new parenteral carbapenem. in healthy Japanese male volunteers.In Program and Abstracts of the 42nd Interscience Conference on AntimicrobialAgents and Chemotherapy , abstract A-1941 San Francisco: American Societyfor Microbiology;
    [Google Scholar]
  16. Shibayama T., Matsushita Y., Hirota T., Ikeda T., Kuwahara S. 2006; Pharmacokinetics of CS-023 (RO4908463),a novel parenteral carbapenem, in healthy male Caucasian volunteers. Antimicrob Agents Chemother 50:4186–4188 [CrossRef]
    [Google Scholar]
  17. Shibayama T., Matsushita Y., Kurihara A., Hirota T., Ikeda T. 2007; Prediction of pharmacokinetics ofCS-023 (RO4908463), a novel parenteral carbapenem antibiotic, inhumans using animal data. Xenobiotica 37:91–102 [CrossRef]
    [Google Scholar]
  18. Vogelman B. S., Craig W. A. 1985; Postantibiotic effects. J Antimicrob Chemother 15 (Suppl. A):37–46 [CrossRef]
    [Google Scholar]
  19. Zhanel G. G., Hoban D. J., Harding G. K. M. 1991; The postantibiotic effect: a review of in vitro andin vivo data. DICP 25:153–163
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jmm/10.1099/jmm.0.017905-0
Loading
/content/journal/jmm/10.1099/jmm.0.017905-0
Loading

Data & Media loading...

Most cited this month Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error